243 related articles for article (PubMed ID: 35285916)
21. Inverse stage migration patterns in North American patients undergoing local prostate cancer treatment: a contemporary population-based update in light of the 2012 USPSTF recommendations.
Leyh-Bannurah SR; Karakiewicz PI; Pompe RS; Preisser F; Zaffuto E; Dell'Oglio P; Briganti A; Nafez O; Fisch M; Steuber T; Graefen M; Budäus L
World J Urol; 2019 Mar; 37(3):469-479. PubMed ID: 29992380
[TBL] [Abstract][Full Text] [Related]
22. Stage-specific incidence rates and trends of prostate cancer by age, race, and ethnicity, United States, 2004-2014.
Li J; Siegel DA; King JB
Ann Epidemiol; 2018 May; 28(5):328-330. PubMed ID: 29678312
[TBL] [Abstract][Full Text] [Related]
23. Trends in United States Prostate Cancer Incidence Rates by Age and Stage, 1995-2012.
Hoffman RM; Meisner AL; Arap W; Barry M; Shah SK; Zeliadt SB; Wiggins CL
Cancer Epidemiol Biomarkers Prev; 2016 Feb; 25(2):259-63. PubMed ID: 26646364
[TBL] [Abstract][Full Text] [Related]
24. Association of Prostate-Specific Antigen Screening Rates With Subsequent Metastatic Prostate Cancer Incidence at US Veterans Health Administration Facilities.
Bryant AK; Lee KM; Alba PR; Murphy JD; Martinez ME; Natarajan L; Green MD; Dess RT; Anglin-Foote TR; Robison B; DuVall SL; Lynch JA; Rose BS
JAMA Oncol; 2022 Dec; 8(12):1747-1755. PubMed ID: 36279204
[TBL] [Abstract][Full Text] [Related]
25. Development and Validation of a Lookup Table for the Prediction of Metastatic Prostate Cancer According to Prostatic-specific Antigen Value, Clinical Tumor Stage, and Gleason Grade Groups.
Preisser F; Bandini M; Nazzani S; Mazzone E; Marchioni M; Tian Z; Chun FKH; Saad F; Briganti A; Haese A; Montorsi F; Huland H; Graefen M; Tilki D; Karakiewicz PI
Eur Urol Oncol; 2020 Oct; 3(5):631-639. PubMed ID: 31411975
[TBL] [Abstract][Full Text] [Related]
26. Recent decline in prostate cancer incidence in the United States, by age, stage, and Gleason score.
Herget KA; Patel DP; Hanson HA; Sweeney C; Lowrance WT
Cancer Med; 2016 Jan; 5(1):136-41. PubMed ID: 26628287
[TBL] [Abstract][Full Text] [Related]
27. An Up-to-date Assessment of US Prostate Cancer Incidence Rates by Stage and Race: A Novel Approach Combining Multiple Imputation with Age and Delay Adjustment.
Cook MB; Hurwitz LM; Geczik AM; Butler EN
Eur Urol; 2021 Jan; 79(1):33-41. PubMed ID: 33092896
[TBL] [Abstract][Full Text] [Related]
28. Prostate-specific antigen testing after the US Preventive Services Task Force recommendation: a population-based analysis of electronic health data.
Frendl DM; Epstein MM; Fouayzi H; Krajenta R; Rybicki BA; Sokoloff MH
Cancer Causes Control; 2020 Sep; 31(9):861-867. PubMed ID: 32556947
[TBL] [Abstract][Full Text] [Related]
29. Racial and Ethnic Disparities in Prostate Cancer Outcomes in the Veterans Affairs Health Care System.
Yamoah K; Lee KM; Awasthi S; Alba PR; Perez C; Anglin-Foote TR; Robison B; Gao A; DuVall SL; Katsoulakis E; Wong YN; Markt SC; Rose BS; Burri R; Wang C; Aboiralor O; Fink AK; Nickols NG; Lynch JA; Garraway IP
JAMA Netw Open; 2022 Jan; 5(1):e2144027. PubMed ID: 35040965
[TBL] [Abstract][Full Text] [Related]
30. Racial and Ethnic Variation in PSA Testing and Prostate Cancer Incidence Following the 2012 USPSTF Recommendation.
Kensler KH; Pernar CH; Mahal BA; Nguyen PL; Trinh QD; Kibel AS; Rebbeck TR
J Natl Cancer Inst; 2021 Jun; 113(6):719-726. PubMed ID: 33146392
[TBL] [Abstract][Full Text] [Related]
31. Trends in distant-stage breast, colorectal, and prostate cancer incidence rates from 1992 to 2004: potential influences of screening and hormonal factors.
McDougall JA; Li CI
Horm Cancer; 2010 Feb; 1(1):55-62. PubMed ID: 21761350
[TBL] [Abstract][Full Text] [Related]
32. Changes in the outcome of prostate biopsies after preventive task force recommendation against prostate-specific antigen screening.
Zakaria AS; Dragomir A; Brimo F; Kassouf W; Tanguay S; Aprikian A
BMC Urol; 2018 Aug; 18(1):69. PubMed ID: 30126402
[TBL] [Abstract][Full Text] [Related]
33. Implications of the United States Preventive Services Task Force Recommendations on Prostate Cancer Stage Migration.
Sheng IY; Wei W; Chen YW; Gilligan TD; Barata PC; Ornstein MC; Rini BI; Garcia JA
Clin Genitourin Cancer; 2021 Feb; 19(1):e12-e16. PubMed ID: 32800474
[TBL] [Abstract][Full Text] [Related]
34. The Effect of Lymph Node Dissection in Metastatic Prostate Cancer Patients Treated with Radical Prostatectomy: A Contemporary Analysis of Survival and Early Postoperative Outcomes.
Mazzone E; Preisser F; Nazzani S; Tian Z; Bandini M; Gandaglia G; Fossati N; Montorsi F; Graefen M; Shariat SF; Saad F; Briganti A; Karakiewicz PI
Eur Urol Oncol; 2019 Sep; 2(5):541-548. PubMed ID: 31411992
[TBL] [Abstract][Full Text] [Related]
35. Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities.
Würnschimmel C; Wenzel M; Collà Ruvolo C; Nocera L; Tian Z; Saad F; Briganti A; Shariat SF; Mandel P; Chun FKH; Tilki D; Graefen M; Karakiewicz PI
World J Urol; 2021 Oct; 39(10):3781-3787. PubMed ID: 33978812
[TBL] [Abstract][Full Text] [Related]
36. Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States.
Mahal BA; Chen YW; Muralidhar V; Mahal AR; Choueiri TK; Hoffman KE; Hu JC; Sweeney CJ; Yu JB; Feng FY; Kim SP; Beard CJ; Martin NE; Trinh QD; Nguyen PL
Ann Oncol; 2017 May; 28(5):1098-1104. PubMed ID: 28453693
[TBL] [Abstract][Full Text] [Related]
37. Trends in the stage specific incidence of prostate carcinoma in the Detroit metropolitan area, 1973-1994.
Schwartz KL; Severson RK; Gurney JG; Montie JE
Cancer; 1996 Sep; 78(6):1260-6. PubMed ID: 8826949
[TBL] [Abstract][Full Text] [Related]
38. Trends for Stage and Grade Group of Prostate Cancer in the US (2010-2016).
Schmanke K; Okut H; Ablah E
Urology; 2021 Mar; 149():110-116. PubMed ID: 33227304
[TBL] [Abstract][Full Text] [Related]
39. Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications.
Gershman B; Van Houten HK; Herrin J; Moreira DM; Kim SP; Shah ND; Karnes RJ
Eur Urol; 2017 Jan; 71(1):55-65. PubMed ID: 26995328
[TBL] [Abstract][Full Text] [Related]
40. The role of increasing detection in the rising incidence of prostate cancer.
Potosky AL; Miller BA; Albertsen PC; Kramer BS
JAMA; 1995 Feb; 273(7):548-52. PubMed ID: 7530782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]